Valuation : Morepen Laboratories Limited

Market Cap 1.85TCr 19Cr 17Cr 16Cr 14Cr 27Cr 27Cr 185.75Cr 72Cr 934.92Cr 73Cr 71Cr 3.1TCr P/E 2024
22.4x
P/E 2025 21.8x
Enterprise Value 1.85TCr 19Cr 17Cr 16Cr 14Cr 27Cr 27Cr 185.74Cr 72Cr 934.87Cr 73Cr 71Cr 3.1TCr EV / Sales 2024
1.27x
EV / Sales 2025 1.45x
Free-Float
57.31%
Yield 2024 *
-
Yield 2025 0.42%
1 day+9.81%
1 week+10.60%
Current month+86.17%
1 month+92.03%
3 months+151.52%
6 months+143.16%
Current year+158.56%
1 week 92.7
Extreme 92.7
106.37
1 month 55.91
Extreme 55.91
106.37
Current year 33.05
Extreme 33.05
106.37
1 year 33.05
Extreme 33.05
106.37
3 years 31.3
Extreme 31.3
106.37
5 years 23.6
Extreme 23.6
106.37
10 years 7.2
Extreme 7.2
106.37
Manager TitleAgeSince
Chief Executive Officer 58 01/07/2026
Chief Executive Officer 62 01/02/1992
Director of Finance/CFO 59 03/04/2002
Director TitleAgeSince
Chairman 62 01/02/1992
Director/Board Member 58 13/08/2019
Director/Board Member - 22/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
+9.81%+10.60% - - 61Cr
-0.13%-6.44%+60.47%+112.05% 1,04700Cr
+0.85%-0.81%+52.77%+63.15% 65TCr
-1.03%-3.58%+22.87%+73.29% 45TCr
-1.46%-4.50%+37.43%+38.41% 35TCr
-0.72%-2.89%+21.86%+36.79% 29TCr
-1.19%-2.21%+1.35%+12.29% 25TCr
-1.05%-1.57%+51.40%+68.55% 23TCr
+0.08%-1.78%-17.64%-54.29% 20TCr
-2.14%-0.30%+29.42%+89.10% 18TCr
Average +0.29%-2.68%+28.88%+48.82% 40.66TCr
Weighted average by Cap. -0.48%-3.46%+38.66%+65.51%

Financials

2024 2025
Net sales 1.7TCr 18Cr 15Cr 14Cr 13Cr 25Cr 25Cr 170.69Cr 67Cr 859.11Cr 67Cr 65Cr 2.85TCr 1.81TCr 19Cr 16Cr 15Cr 14Cr 26Cr 26Cr 181.69Cr 71Cr 914.47Cr 71Cr 70Cr 3.03TCr
Net income 96Cr 1.01Cr 86.7L 81.29L 74.2L 1.4Cr 1.4Cr 9.64Cr 3.76Cr 49Cr 3.78Cr 3.7Cr 160.95Cr 118.02Cr 1.23Cr 1.06Cr 99.77L 91.07L 1.72Cr 1.72Cr 12Cr 4.62Cr 60Cr 4.64Cr 4.54Cr 197.54Cr
Net Debt 12Cr 12.61L 10.87L 10.19L 9L 17.52L 17.58L 1.21Cr 47.17L 6.08Cr 47.35L 46.32L 20Cr -9L -9.71T -8.37T -7.84T -7.16T -13.49T -13.53T -93.07T -36.31T -5L -36.46T -35.66T -15.53L
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,814
Date Price Change Volume
28/26/28 ₹106.19 +9.81% 3,90,01,643
27/26/27 ₹96.70 -0.29% 1,46,19,445
26/26/26 ₹96.98 +3.28% 1,17,01,259
25/26/25 ₹93.90 -1.39% 89,74,075
24/26/24 ₹95.22 -0.82% 1,66,86,161